CUTIA-B(02487)
5.900-0.500-7.81%
Login to post
- CommunityCommunity
- NewsNews
- ProfileProfile
- AnnouncementsAnnouncements
- Cutia Therapeutics Completes Trial of Adipose Accumulation Drug to Show Safety, EfficacyCutia Therapeutics Completes Trial of Adipose Accumulation Drug to Show Safety, Efficacy
MT Newswires Live · 2024-12-31
- Sa Sa International CFO Resigns; Successor NamedSa Sa International CFO Resigns; Successor Named
MT Newswires Live · 2024-12-13
- Cutia Therapeutics Obesity Drug Reaches Meaningful End to Clinical TrialCutia Therapeutics Obesity Drug Reaches Meaningful End to Clinical Trial
MT Newswires Live · 2024-11-29
- Cutia Therapeutics Phase III Trial for Skin Treatments Presented in Annual CDA MeetingCutia Therapeutics Phase III Trial for Skin Treatments Presented in Annual CDA Meeting
MT Newswires Live · 2024-11-28
- Cutia Therapeutics CEO Buys More Company SharesCutia Therapeutics CEO Buys More Company Shares
MT Newswires Live · 2024-11-18
- Cutia Therapeutics' Topical Acne Treatment Gets China Marketing ApprovalCutia Therapeutics' Topical Acne Treatment Gets China Marketing Approval
MT Newswires Live · 2024-11-12
- BRIEF-Cutia Therapeutics Says CU-10201 (Topical 4% Minocycline Foam) Obtained Marketing Approval By NMPABRIEF-Cutia Therapeutics Says CU-10201 (Topical 4% Minocycline Foam) Obtained Marketing Approval By NMPA
Reuters · 2024-11-12
- Cutia Therapeutics - Cu-10201 (Topical 4% Minocycline Foam) Obtained Marketing Approval by NmpaCutia Therapeutics - Cu-10201 (Topical 4% Minocycline Foam) Obtained Marketing Approval by Nmpa
THOMSON REUTERS · 2024-11-11
- Cutia Therapeutics CEO Increase Shareholding in CompanyCutia Therapeutics CEO Increase Shareholding in Company
MT Newswires Live · 2024-11-11
- Insider Buyers Lose Additional CN¥234k As Cutia Therapeutics Dips To HK$3.5b
Simply Wall St. · 2024-11-04
Insider Buyers Lose Additional CN¥234k As Cutia Therapeutics Dips To HK$3.5b - Cutia Therapeutics' Phase 2 Trial of Drug for Adipose Accumulation-Related Diseases Complete Database LockCutia Therapeutics' Phase 2 Trial of Drug for Adipose Accumulation-Related Diseases Complete Database Lock
MT Newswires Live · 2024-10-31
- Cutia Therapeutics Records 130% Higher Revenue from Commercialized Products in Nine Months to SeptemberCutia Therapeutics Records 130% Higher Revenue from Commercialized Products in Nine Months to September
MT Newswires Live · 2024-10-31
- BRIEF-Cutia Therapeutics Posts 9M Revenue Of Group's Commercialized Products Rmb148.9 MillionBRIEF-Cutia Therapeutics Posts 9M Revenue Of Group's Commercialized Products Rmb148.9 Million
Reuters · 2024-10-31
- Cutia Therapeutics - 9M Revenue of Group's Commercialized Products RMB148.9 MlnCutia Therapeutics - 9M Revenue of Group's Commercialized Products RMB148.9 Mln
THOMSON REUTERS · 2024-10-31
- Cutia Therapeutics CEO Acquires 20,000 Shares in Company; Shares Rise 5%Cutia Therapeutics CEO Acquires 20,000 Shares in Company; Shares Rise 5%
MT Newswires Live · 2024-10-17
- BRIEF-Cutia Therapeutics Announces Increase In Shareholding By CEOBRIEF-Cutia Therapeutics Announces Increase In Shareholding By CEO
Reuters · 2024-10-17
- Cutia Therapeutics - CEO Purchased 20,000 Shares of Co on 15 and 16 Oct for HK$241,116Cutia Therapeutics - CEO Purchased 20,000 Shares of Co on 15 and 16 Oct for HK$241,116
THOMSON REUTERS · 2024-10-16
- Cutia Therapeutics - Increase in Shareholding by Chief Executive OfficerCutia Therapeutics - Increase in Shareholding by Chief Executive Officer
THOMSON REUTERS · 2024-10-16
- Cutia Therapeutics CEO Buys 8,000 SharesCutia Therapeutics CEO Buys 8,000 Shares
MT Newswires Live · 2024-10-14
- BRIEF-Cutia Therapeutics Says Increase In Shareholding By CEO And Executive DirectorBRIEF-Cutia Therapeutics Says Increase In Shareholding By CEO And Executive Director
Reuters · 2024-10-14
High
6.400
Open
6.400
Volume%
1.24
Low
5.820
Close
6.400
T/O Rate
0.94%
抱歉，当前请求异常(-1)
Terms and Conditions·Privacy Policy
Company: TTMF Limited. Tech supported by Xiangshang Yixin.
Email：uservice@ttm.financial